madman
Super Moderator
* Acute ischemic priapism is a time-dependent urologic emergency requiring rapid intervention to prevent irreversible tissue damage
* Experimental studies demonstrate that prolonged hypoxia, acidosis, and glucopenia lead to progressive cavernosal smooth muscle injury and DNA fragmentation.2 As ischemia persists beyond 24 to 48 hours, smooth muscle viability declines significantly, and the likelihood of recovery of erectile function becomes extremely low.
==============
Prolonged ischemic priapism remains one of the most challenging emergencies in sexual medicine and reconstructive urology. Persistent corporal ischemia can lead to irreversible cavernosal smooth muscle injury, often resulting in permanent erectile dysfunction and significant psychological distress. The optimal management of these complex cases—particularly the timing of penile prosthesis implantation—continues to evolve.
At the upcoming AUA Annual Meeting, our plenary session, “Second Opinion Case: Prolonged Priapism Management—Is Immediate Prosthesis Now the Standard of Care?,” will review contemporary surgical strategies.
Experimental studies demonstrate that prolonged hypoxia, acidosis, and glucopenia lead to progressive cavernosal smooth muscle injury and DNA fragmentation.2 As ischemia persists beyond 24 to 48 hours, smooth muscle viability declines significantly, and the likelihood of recovery of erectile function becomes extremely low.
This is typically followed by intracavernosal injection of alpha-adrenergic agonists, most commonly phenylephrine. Phenylephrine induces cavernosal smooth muscle contraction and improves venous outflow. These interventions are often effective when initiated early. After about 48 hours, alpha-adrenergic agonists are no longer effective as the smooth muscle is necrotic and cannot contract; thus, detumescence cannot occur.1
In patients with recurrent ischemic or stuttering priapism, preventive medical therapies may also be considered. These include oral 5-α reductase inhibitors, baclofen, ketoconazole, or phosphodiesterase-5 inhibitors used paradoxically to stabilize nitric oxide signaling pathways.4 However, evidence supporting these preventive strategies remains limited and largely derived from small case series.
When priapism persists despite aspiration and pharmacologic therapy—particularly beyond 36 to 48 hours of ischemia—the probability of functional recovery becomes extremely low. At this stage, escalation to surgical management is generally required (Table 1).
Recent literature increasingly supports early prosthesis implantation, typically within the first 3 weeks following the priapism episode, before significant fibrosis develops.
Advantages of malleable implants include:
Our plenary session will present a challenging clinical case and bring together an expert panel to discuss evolving management strategies. Attendees are invited to participate in this discussion as we explore whether early penile prosthesis implantation should become the new standard of care for prolonged ischemic priapism. We hope you will join us on Monday, May 18.
* Experimental studies demonstrate that prolonged hypoxia, acidosis, and glucopenia lead to progressive cavernosal smooth muscle injury and DNA fragmentation.2 As ischemia persists beyond 24 to 48 hours, smooth muscle viability declines significantly, and the likelihood of recovery of erectile function becomes extremely low.
==============
Prolonged ischemic priapism remains one of the most challenging emergencies in sexual medicine and reconstructive urology. Persistent corporal ischemia can lead to irreversible cavernosal smooth muscle injury, often resulting in permanent erectile dysfunction and significant psychological distress. The optimal management of these complex cases—particularly the timing of penile prosthesis implantation—continues to evolve.
At the upcoming AUA Annual Meeting, our plenary session, “Second Opinion Case: Prolonged Priapism Management—Is Immediate Prosthesis Now the Standard of Care?,” will review contemporary surgical strategies.
Time‐Critical Pathophysiology
Acute ischemic priapism is a time-dependent urologic emergency requiring rapid intervention to prevent irreversible tissue damage. Cavernosal blood gas is recommended to confirm the diagnosis, and this will show hypoxic, hypercarbic, and acidotic blood. In unclear cases, a duplex Doppler ultrasound can be used to assess for low or absent arterial inflow.1 Current AUA/Sexual Medicine Society of North America guidelines recommend a stepwise approach beginning with corporal aspiration and intracavernosal injection of alpha-adrenergic agonists such as phenylephrine. If these measures fail, surgical procedures are recommended.1Experimental studies demonstrate that prolonged hypoxia, acidosis, and glucopenia lead to progressive cavernosal smooth muscle injury and DNA fragmentation.2 As ischemia persists beyond 24 to 48 hours, smooth muscle viability declines significantly, and the likelihood of recovery of erectile function becomes extremely low.
Nonsurgical Management
Initial management focuses on rapid detumescence and restoration of corporal oxygenation. Both the AUA/Sexual Medicine Society of North America and the European Association of Urology guidelines recommend corporal aspiration and irrigation as first-line therapy.1,3 Removal of deoxygenated blood reduces intracavernosal pressure and may restore arterial inflow.This is typically followed by intracavernosal injection of alpha-adrenergic agonists, most commonly phenylephrine. Phenylephrine induces cavernosal smooth muscle contraction and improves venous outflow. These interventions are often effective when initiated early. After about 48 hours, alpha-adrenergic agonists are no longer effective as the smooth muscle is necrotic and cannot contract; thus, detumescence cannot occur.1
In patients with recurrent ischemic or stuttering priapism, preventive medical therapies may also be considered. These include oral 5-α reductase inhibitors, baclofen, ketoconazole, or phosphodiesterase-5 inhibitors used paradoxically to stabilize nitric oxide signaling pathways.4 However, evidence supporting these preventive strategies remains limited and largely derived from small case series.
When priapism persists despite aspiration and pharmacologic therapy—particularly beyond 36 to 48 hours of ischemia—the probability of functional recovery becomes extremely low. At this stage, escalation to surgical management is generally required (Table 1).
Shunts
After conservative measures fail, a distal corporoglanular shunt, with or without tunneling, is typically the next step (Figure 1).1 Various distal shunts have been described and work by creating a fistula between the cavernosa and spongiosum. This decompression then allows for the venous outflow to be restored. Percutaneous shunts include the Winter’s shunt, which uses a biopsy needle through the distal corpora or Ebbehoj’s shunt, which uses an 11-blade to make multiple stab incisions. Open distal shunts include a T-shunt, where a scalpel is inserted into the glans and rotated 90° away from the urethra, or the Al-Ghorab shunt, when the tip of the distal tunica albuginea is excised. These latter 2 shunts may include corporal tunneling, usually with an 8F Hegar dilator for further decompression.5 Proximal shunts are largely of historical interest and should be avoided in the modern era, as refractory cases are often considered for early penile implant placement.1
Penoscrotal Decompression
A surgical approach that has been recently popularized is penoscrotal decompression, which involves a penoscrotal incision, corporotomy performance along with proximal and distal dilation using a pediatric Yankauer catheter, followed by irrigation. This has been shown to be successful even in prolonged priapism cases or after failed distal shunts. This technique is thought to disrupt the ischemic coagulum and create an internal shunt, which restores venous outflow.6 A recent survey has shown that surgeons equally select this technique vs penile implantation for failed distal shunts.7Time‐Adapted Treatment Strategy
Given the irreversible nature of prolonged ischemia, many clinicians now employ a time-adapted treatment strategy for refractory ischemic priapism. If irreversible tissue injury is suspected, penile prosthesis implantation provides definitive management by resolving the painful priapic episode while restoring penile rigidity. Historically, prosthesis implantation was delayed for several months to allow inflammation to subside. However, delayed implantation has been shown to increase complication rates, likely due to the presence of dense corporal fibrosis, making dilation technically challenging.8Recent literature increasingly supports early prosthesis implantation, typically within the first 3 weeks following the priapism episode, before significant fibrosis develops.
Early vs Delayed Implantation
Several retrospective studies have compared outcomes of early vs delayed penile prosthesis implantation in patients with prolonged ischemic priapism (Figures 2 and 3). Early implantation—generally within 3 weeks of the priapism episode—has been associated with improved surgical outcomes and higher patient satisfaction.9 In contrast, delayed implantation is often complicated by dense corporal fibrosis, making dilation more difficult and increasing the risk of perforation or device malposition (Table 2). However, there are numerous techniques now being employed to aid in delayed implant insertion. Preoperative phosphodiesterase inhibitors and vacuum erection devices are thought to help soften fibrosis and increase length. Intraoperatively, extended or multiple corporotomies, corporal excavation, use of cavernotomes or backward cutting scissors, and/or downsizing cylinders have increased the success of these operations.10
Prosthesis Selection
Prosthesis choice is another important consideration. Both malleable penile prostheses and inflatable penile prostheses may be used; however, malleable implants are often favored in acute or early settings.Advantages of malleable implants include:
- Faster and technically simpler implantation
- Lower infection risk in inflamed tissues
- Greater availability in urgent settings
- Possibility of later conversion to inflatable prostheses
Looking Ahead
Although evidence increasingly supports early penile prosthesis implantation for prolonged ischemic priapism, high-level randomized data remain limited. Most available evidence derives from retrospective series and systematic reviews.Our plenary session will present a challenging clinical case and bring together an expert panel to discuss evolving management strategies. Attendees are invited to participate in this discussion as we explore whether early penile prosthesis implantation should become the new standard of care for prolonged ischemic priapism. We hope you will join us on Monday, May 18.
